Local modulation of S1P receptor signaling with nanofibrous hyaluronic acid scaffolds as a regenerative immunotherapy following critical volumetric muscle loss injury
使用纳米纤维透明质酸支架局部调节 S1P 受体信号作为关键体积肌肉损失损伤后的再生免疫疗法
基本信息
- 批准号:10390016
- 负责人:
- 金额:$ 4.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-01 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:AffectAllogenicAnti-Inflammatory AgentsAttentionAttenuatedAutologousAwardBone MarrowCellsCharacteristicsChemotactic FactorsChimera organismChronicClinicalClinical TreatmentCoculture TechniquesComplexCuesCytometryDataDefectEnsureEnvironmentExcisionFellowshipFibrosisFrequenciesFutureG-Protein-Coupled ReceptorsGoldHistologicHyaluronic AcidImmuneImmune responseImmunotherapyImpairmentIn VitroInfiltrationInflammationInflammatoryInjuryIntegrinsIsometric ExerciseKnock-outLifeMediatingMedicalMilitary PersonnelModelingMolecularMusMuscleMuscle FibersMuscle functionMuscle satellite cellMuscular AtrophyNecrosisOutcome MeasurePainPathologicPathologyPharmacologyPhenotypePlayProductionProfibrotic signalQuality of lifeReceptor SignalingRecoveryRecovery of FunctionRegenerative engineeringRoleSPHK1 enzymeScientistSignal TransductionSiteSphingolipidsSphingosineStimulusStructureSurgical FlapsTNF geneTechniquesTestingTherapeuticThickTimeTissuesTorqueTrainingTransforming Growth Factor betaTraumaTraumatic injuryWorkanalytical methodantagonistbonecell injurydesigndisabilitydraining lymph nodeexperienceexperimental studyfunctional disabilityfunctional outcomesfunctional restorationhistological stainsinjuredinnovationinorganic phosphatelimb injurylipid metabolismlipidomicsmacrophagemesenchymal stromal cellmonocytemuscle regenerationmyogenesisnanofibernovelpre-clinicalprogenitorquadriceps musclereceptorrecruitregenerativeregenerative therapyrepairedresponsescaffoldsevere injurysphingosine kinasestandard carestandard of caresuccesstissue reconstructiontraffickingvolumetric muscle loss
项目摘要
PROJECT SUMMARY
Extremity trauma is an increasingly significant clinical challenge among both civilian and military populations, particularly
in cases that result in volumetric muscle loss (VML). Current standards of treatment for VML fail to successfully restore
muscle function after injury and result in fibrosis rather than newly formed muscle fibers. Many approaches aimed to treat
VML fail to pay attention to the local endogenous immune response of the host which underlies the aberrant chronic
inflammation and fibrotic signaling characteristic of VML pathology. VML injury rapidly leads to degeneration and necrosis
of damaged myofibers and the invasion and activation of a broad range of immune cells, including monocytes and
macrophages. This creates an environment rich in both pro- and anti-inflammatory cues that most often leads to pathological
fibrosis. Designing anti-inflammatory strategies to reduce overall macrophage burden and promote their removal from sites
of injury is critical to restore function. The study's hypothesis is that sphingosine-1-phophate (S1P), a bioactive signaling
sphingolipid that is produced in tissue upon inflammation, plays a crucial role in the pro-longed immune cell retention
following VML, as S1P is a potent chemoattractant towards injury. S1P signals through 5 known G protein-coupled
receptors (S1PR1-5) and therefore S1P-dependent immune cell responses are dependent on their S1PR profile. S1P has
been implicated in propagating tissue fibrosis via the S1P/S1PR3 signaling axis and our previous studies reveal a crucial
role for S1PR3 in promoting immune cell niche occupancy or egress. In Aim 1, the role of S1P on aberrant immune cell
retention and macrophage-mediated fibrosis will be evaluated in a murine quadriceps VML model via lipidomic analysis of
injured muscle and single-cell time-of-flight mass cytometry (CyTOF) from injured muscle tissue and its draining lymph
node. Sphingosine kinase 1 knockout (SPHK1-/-) mice will be utilized to directly assess the role of S1P in impairing efficient
immune cell egress and mediating pro-fibrotic macrophage signaling on fibroadipogenic progenitors (FAPs) which drives
pathological fibrosis. In Aim 2, the effect of S1PR3 antagonism on promoting immune cell egress and abrogating
macrophage-induced fibrosis to enhance overall muscle recovery after VML injury will be assessed. This will be
accomplished by creating bone marrow chimeras between C57/BL6 mice and S1PR3-/- mice to determine the contribution
of S1PR3 signaling on immune cell recruitment vs egress in a microenvironment of chronic inflammatory stimuli.
Moreover, local, pharmacological antagonism of S1PR3 by delivery of VPC01091 (S1PR3 antagonist) from novel,
nanofibrous hyaluronic acid scaffolds to the injury milieu of critically sized VML defects will be evaluated. Lipidomic and
single-cell CyTOF analysis will be performed to analyze how S1PR3 antagonism affects local lipid metabolism and
inflammation following injury. In addition, structural muscle assessments via histological staining for regenerative muscle
markers will be assessed. Isometric torque production will be quantified as a functional outcome measure to determine if
our therapeutic strategy enhances functional muscle recovery. This study will demonstrate how S1P receptor modulators
can be re-purposed to locally target endogenous repair cells in the host as a novel form of regenerative immunotherapy.
项目摘要
创伤是平民和军事人群中日益重要的临床挑战,特别是
在导致肌肉体积损失(VML)的情况下。目前VML的治疗标准未能成功恢复
损伤后的肌肉功能,并导致纤维化,而不是新形成的肌肉纤维。许多方法旨在治疗
VML未能注意到宿主的局部内源性免疫反应,这是异常慢性免疫的基础。
VML病理学特征性炎症和纤维化信号传导。VML损伤迅速导致变性和坏死
损伤的肌纤维和广泛的免疫细胞的侵入和激活,包括单核细胞和
巨噬细胞这创造了一个富含促炎和抗炎信号的环境,这通常会导致病理性炎症。
纤维化设计抗炎策略以减少总体巨噬细胞负荷并促进其从部位清除
对恢复功能至关重要。这项研究的假设是,鞘氨醇-1-磷酸(S1 P),一种生物活性的信号传导,
在炎症时在组织中产生的鞘脂在延长免疫细胞滞留中起着至关重要的作用
在VML之后,因为S1 P是针对损伤的有效化学引诱物。S1 P信号通过5个已知的G蛋白偶联的
受体(S1 PR 1 -5),因此S1 P依赖性免疫细胞应答依赖于它们的S1 PR谱。S1 P有
通过S1 P/S1 PR 3信号轴参与组织纤维化的传播,我们以前的研究揭示了一个关键的
S1 PR 3在促进免疫细胞小生境占据或排出中的作用。目的1:S1 P在异常免疫细胞中的作用
通过脂质组学分析,在鼠股四头肌VML模型中评估巨噬细胞介导的纤维化和尿潴留。
损伤肌肉和来自损伤肌肉组织及其引流淋巴液的单细胞飞行时间质谱仪(CyTOF)
node.鞘氨醇激酶1敲除(SPHK 1-/-)小鼠将用于直接评估S1 P在损害有效的细胞凋亡中的作用。
免疫细胞外出并介导纤维脂肪生成祖细胞(FAP)上的促纤维化巨噬细胞信号传导,
病理性纤维化在目的2中,研究了S1 PR 3拮抗作用对促进免疫细胞排出和消除免疫抑制的作用。
将评估巨噬细胞诱导的纤维化对增强VML损伤后的总体肌肉恢复的作用。这将是
通过在C57/BL 6小鼠和S1 PR 3-/-小鼠之间产生骨髓嵌合体来完成,以确定贡献
在慢性炎症刺激的微环境中,S1 PR 3信号对免疫细胞募集与流出的影响。
此外,通过递送来自新的,
将评估纳米纤维透明质酸支架对临界尺寸的VML缺陷的损伤环境的影响。脂质组学和
将进行单细胞CyTOF分析,以分析S1 PR 3拮抗作用如何影响局部脂质代谢,
损伤后的炎症。此外,通过再生肌肉的组织学染色进行的结构肌肉评估
标记将被评估。将等长扭矩产生量化为功能结局指标,以确定
我们的治疗策略增强功能性肌肉恢复。这项研究将证明S1 P受体调节剂
可以被重新用于局部靶向宿主中的内源性修复细胞,作为再生免疫疗法的新形式。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lauren Alexandra Hymel其他文献
Lauren Alexandra Hymel的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lauren Alexandra Hymel', 18)}}的其他基金
Local modulation of S1P receptor signaling with nanofibrous hyaluronic acid scaffolds as a regenerative immunotherapy following critical volumetric muscle loss injury
使用纳米纤维透明质酸支架局部调节 S1P 受体信号作为关键体积肌肉损失损伤后的再生免疫疗法
- 批准号:
10591401 - 财政年份:2022
- 资助金额:
$ 4.6万 - 项目类别:
相似海外基金
HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
- 批准号:
10039902 - 财政年份:2022
- 资助金额:
$ 4.6万 - 项目类别:
EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
- 批准号:
21K15925 - 财政年份:2021
- 资助金额:
$ 4.6万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
- 批准号:
21K08410 - 财政年份:2021
- 资助金额:
$ 4.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
- 批准号:
20K21672 - 财政年份:2020
- 资助金额:
$ 4.6万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
- 批准号:
18K16395 - 财政年份:2018
- 资助金额:
$ 4.6万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
- 批准号:
17K10951 - 财政年份:2017
- 资助金额:
$ 4.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
- 批准号:
370541 - 财政年份:2017
- 资助金额:
$ 4.6万 - 项目类别:
Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
- 批准号:
16K10863 - 财政年份:2016
- 资助金额:
$ 4.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
- 批准号:
276706135 - 财政年份:2015
- 资助金额:
$ 4.6万 - 项目类别:
Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
- 批准号:
15H04915 - 财政年份:2015
- 资助金额:
$ 4.6万 - 项目类别:
Grant-in-Aid for Scientific Research (B)